Page 23 of 24
OG28.1-4,OG30.1-2 | Infertility and Endocrine Gynaecology — Assignment
CLINICAL SCENARIO
You are a junior doctor in the gynaecology outpatient clinic. A 27-year-old woman presents with oligomenorrhoea (5–6 menstrual periods per year) for 3 years and inability to conceive for 18 months (primary infertility). She has moderate acne and increased facial hair. Her BMI is 30. Her husband's semen analysis is normal. This assignment asks you to apply a systematic clinical framework — from accurate diagnosis to individualized management — for this common and clinically important presentation.
Instructions
Write a structured clinical analysis of this patient using the section headings provided. Your response must: (1) apply the Rotterdam 2003 criteria correctly and explicitly to reach a diagnosis; (2) construct a stepwise evidence-based management plan individualized to her dual presenting problem (menstrual regulation AND infertility); (3) address the long-term metabolic and endometrial risks; and (4) identify what clinical features or investigation results would require you to revise your diagnosis. Write in clear medical prose. Do not merely list facts — demonstrate clinical reasoning by explaining WHY each decision is made.
Length: 900–1,300 words (all five sections combined). Quality of reasoning matters more than word count.
What to Submit
Section 1: Applying the Rotterdam 2003 Criteria (approx. 200 words)
Guidance: State the three Rotterdam 2003 diagnostic criteria explicitly. Map each criterion to the clinical features described in this patient. Indicate which criteria she satisfies and which require investigation to confirm. State what investigations (and specific thresholds) are needed to objectively confirm each Rotterdam criterion. State which conditions must be excluded before finalising the diagnosis and name the investigations used to exclude them.
Section 2: Pathophysiology Linking Obesity, Insulin Resistance, and Anovulation (approx. 200 words)
Guidance: Explain the insulin resistance — hyperinsulinaemia — androgen excess vicious cycle that drives both the hyperandrogenism and the anovulation in this patient. Use her BMI of 30 as a specific clinical anchor — explain why adiposity worsens insulin resistance in PCOS. Explain how hyperinsulinaemia directly stimulates ovarian theca-cell androgen production and suppresses hepatic SHBG synthesis. Show how this produces functional hyperandrogenism even when total testosterone is only mildly elevated.
Section 3: Stepwise Management Plan — Menstrual Regulation and Metabolic Risk (approx. 250 words)
Guidance: She is NOT currently seeking fertility. Construct a tiered management plan: (a) first-line non-pharmacological (lifestyle modification — specify the weight-loss target in percentage terms and explain the physiological mechanism by which it restores ovulation); (b) pharmacological menstrual regulation (specify the drug class, the rationale for choice, the mechanism of action, and how it protects the endometrium); (c) pharmacological treatment of hirsutism/acne (drug class, mechanism, expected timeline for effect); (d) metabolic risk surveillance (which parameters to monitor, at what interval). Note any contraindications relevant to this patient.
Section 4: Management Plan for Fertility — When She is Ready to Conceive (approx. 200 words)
Guidance: She now wishes to conceive. Outline the stepwise ovulation induction approach: (a) state first-line ovulation induction agent and the evidence base (name the key trial); (b) explain what monitoring is required during induction and why; (c) describe the criteria for escalating to gonadotrophins; (d) state when IVF is appropriate in PCOS-related anovulatory infertility. Address OHSS prevention — state the specific features that signal high risk of OHSS in PCOS and the strategy used to reduce this risk.
Section 5: Long-Term Complications and Diagnostic Red Flags (approx. 150 words)
Guidance: Describe the three major long-term risks of untreated PCOS in this patient: (a) endometrial protection — explain the mechanism by which chronic anovulation creates endometrial cancer risk and the minimum frequency of progestogen-induced withdrawal bleed that is considered protective; (b) metabolic syndrome and type 2 diabetes risk — state the recommended screening interval for glucose intolerance; (c) cardiovascular risk — name the lipid and blood pressure targets. Then specify two clinical features (one symptom, one investigation result) that would require you to abandon the PCOS diagnosis and pursue a different diagnosis. Justify your answer with reference to the differential diagnosis.
Grading Rubric — Infertility and Endocrine Gynaecology Assignment Rubric
| Criterion | Points | Full-marks descriptor |
|---|---|---|
| Rotterdam 2003 criteria application: correct identification of all three criteria, accurate mapping to the case, and specification of confirmatory investigations with thresholds | 20 pts | All three Rotterdam criteria stated accurately; mapped correctly to the case with appropriate investigations and exclusion workup specified (TSH, prolactin, 17-OHP, ultrasound follicle count threshold stated) |
| Pathophysiology: accurate description of insulin resistance — hyperinsulinaemia — androgen excess cycle with SHBG suppression mechanism and link to anovulation | 20 pts | Complete mechanistic explanation: insulin resistance → hyperinsulinaemia → theca-cell LH hyperstimulation AND SHBG suppression → functional hyperandrogenism → anovulation; BMI's role in IR correctly articulated |
| Management plan — menstrual regulation and metabolic risk: appropriate tiered plan with specific drug names, mechanism, endometrial protection strategy, and surveillance schedule | 25 pts | Lifestyle modification with specific 5–10% weight-loss target and mechanism; COCP with anti-androgenic progestogen named with mechanism; hirsutism treatment timeline stated (6–9 months); metabolic surveillance intervals correct (annual OGTT) |
| Fertility management and OHSS prevention: letrozole as first-line with PPCOS II trial cited; correct escalation pathway; OHSS risk features and prevention strategy in PCOS stated | 20 pts | Letrozole named as first-line with PPCOS II evidence; monitoring (ultrasound + oestradiol) described; escalation to gonadotrophins and IVF criteria stated; OHSS risk features in PCOS (high AFC, high AMH, young lean vs obese patient) and coasting/freeze-all strategy named |
| Long-term complications and diagnostic red flags: endometrial protection mechanism, metabolic surveillance, cardiovascular risk, and two specific red flags with differential diagnosis justification | 15 pts | Endometrial cancer risk mechanism (unopposed oestrogen) correctly explained; progestogen-withdrawal frequency stated; annual OGTT and lipid screen; two specific red flags identified (e.g., testosterone >200 ng/dL = tumour; elevated 17-OHP = non-classical CAH) with correct differential |
PEER REVIEW
Review your peer's assignment using the rubric provided. For each criterion: (1) assign a score from the rating scale; (2) write ONE specific sentence explaining why you gave that score, quoting evidence from the response; (3) note one factual point the author got right and one factual point that is missing, incomplete, or clinically inaccurate. Be constructive — your goal is to help your peer strengthen their clinical reasoning before they encounter this case in real practice.